Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
FIBROSARC did not meet its primary PFS endpoint in the final analysi
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
This partnership has led to a 10% boost in delivery speed
Subscribe To Our Newsletter & Stay Updated